[go: up one dir, main page]

AR055191A1 - Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano - Google Patents

Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano

Info

Publication number
AR055191A1
AR055191A1 ARP060104476A ARP060104476A AR055191A1 AR 055191 A1 AR055191 A1 AR 055191A1 AR P060104476 A ARP060104476 A AR P060104476A AR P060104476 A ARP060104476 A AR P060104476A AR 055191 A1 AR055191 A1 AR 055191A1
Authority
AR
Argentina
Prior art keywords
specific
human
hucal
characterization
generation
Prior art date
Application number
ARP060104476A
Other languages
English (en)
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of AR055191A1 publication Critical patent/AR055191A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G01N33/575—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

Métodos para usar regiones de union al antígeno recombinantes y anticuerpos y fragmentos funcionales que contienen regiones de union al antígeno que son específicas para DC38, que desempena un papel integral en varias afecciones o trastornos. Estos anticuerpos como también los métodos para usar esos anticuerpos pueden usarse para tratar, por ejemplo, enfermedades hematologicas tales como mieloma multiple. Reivindicacion 1: Una region aislada de union al antígeno que es específica para CD38, que comprende (i) una region de H-CDR3 que se representa en la SEC ID N°: 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105 o 106 o (ii) una region de H-CDR3 que tiene por lo menos un sesenta por ciento de identidad con una region de H-CDR3 que se representa en la SEC ID N°: 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105 o 106. Reivindicacion 20: Una composicion farmacéutica que comprende un anticuerpo o fragmento funcional de éste de acuerdo con la reivindicacion 4 u 8 y un vehículo o excipiente aceptable desde el punto de vista farmacéutico para esta.
ARP060104476A 2005-10-12 2006-10-12 Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano AR055191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72529705P 2005-10-12 2005-10-12

Publications (1)

Publication Number Publication Date
AR055191A1 true AR055191A1 (es) 2007-08-08

Family

ID=37467440

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060104476A AR055191A1 (es) 2005-10-12 2006-10-12 Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
ARP160102271A AR105490A2 (es) 2005-10-12 2016-07-26 Generación y perfilado de anticuerpos terapéuticos derivados de hucal gold totalmente humanos específicos para cd38 humano

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP160102271A AR105490A2 (es) 2005-10-12 2016-07-26 Generación y perfilado de anticuerpos terapéuticos derivados de hucal gold totalmente humanos específicos para cd38 humano

Country Status (28)

Country Link
US (7) US8088896B2 (es)
EP (3) EP2860192B1 (es)
JP (2) JP5362359B2 (es)
KR (4) KR101574920B1 (es)
CN (4) CN103554260A (es)
AR (2) AR055191A1 (es)
AU (1) AU2006301446B2 (es)
BR (1) BRPI0618399B1 (es)
CA (1) CA2625681C (es)
CY (1) CY1119722T1 (es)
DK (1) DK2860192T3 (es)
ES (1) ES2653664T3 (es)
HR (1) HRP20171978T1 (es)
HU (1) HUE035250T2 (es)
IL (1) IL190665B (es)
LT (1) LT2860192T (es)
ME (1) ME02886B (es)
NO (1) NO344961B1 (es)
NZ (1) NZ566915A (es)
PL (1) PL2860192T3 (es)
PT (1) PT2860192T (es)
RS (1) RS56677B1 (es)
RU (1) RU2425841C2 (es)
SG (1) SG10201400973XA (es)
SI (1) SI2860192T1 (es)
TW (1) TWI428444B (es)
WO (1) WO2007042309A2 (es)
ZA (1) ZA200803208B (es)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
BRPI0618399B1 (pt) * 2005-10-12 2023-10-03 Morphosys Ag Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
PE20120259A1 (es) 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
SI2376116T1 (sl) 2008-12-12 2016-03-31 Boehringer Ingelheim International Gmbh Anti-IGF protitelesa
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
SG188345A1 (en) 2010-09-27 2013-04-30 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP2731970B1 (en) * 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US20130122005A1 (en) 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
NZ756727A (en) 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
AU2013253581B2 (en) 2012-04-23 2019-05-16 Genefrontier Corporation Anti-human CD69 antibody, and use thereof for medical purposes
PL2900232T3 (pl) * 2012-09-25 2018-05-30 Morphosys Ag Kombinacje i ich zastosowania
WO2014068114A1 (en) * 2012-11-05 2014-05-08 Morphosys Ag Radiolabelled antibody and uses thereof
CN104937099B (zh) 2012-11-09 2018-03-30 基因先端领域株式会社 用于治疗癌症的抗adam28抗体
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
PL2968555T3 (pl) 2013-03-13 2020-11-16 Sanofi Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
JP6286532B2 (ja) * 2013-04-29 2018-02-28 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
JP5892117B2 (ja) * 2013-07-17 2016-03-23 横河電機株式会社 フィールド機器及び通信システム
CN103513040B (zh) * 2013-10-16 2015-03-11 常晓天 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
MX385936B (es) 2014-03-28 2025-03-11 Xencor Inc Anticuerpos biespecíficos que se unen a cd38 y cd3.
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
BR112017002136A2 (pt) 2014-08-03 2017-11-21 Pogotec Inc ?sistema de dispositivo eletrônico?
UA122212C2 (uk) 2014-09-09 2020-10-12 Янссен Байотек, Інк. Вид комбінованої терапії з застосуванням антитіла до cd38
EP3212216A4 (en) 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha2b variants
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
IL252467B (en) 2014-11-26 2022-06-01 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
CN107614527A (zh) 2015-03-06 2018-01-19 基因先端领域株式会社 抗人膜类型adam28抗体
JP7068825B2 (ja) 2015-04-08 2022-05-17 ソレント・セラピューティクス・インコーポレイテッド Ｃｄ３８に結合する抗体治療剤
US10533057B2 (en) 2015-05-13 2020-01-14 Morphosys Ag Treatment for multiple myeloma (MM)
MY198983A (en) 2015-05-20 2023-10-06 Janssen Biotech Inc Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HUE066300T2 (hu) 2015-06-24 2024-07-28 Janssen Biotech Inc Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
SG11201803678SA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
AU2016365742A1 (en) 2015-12-07 2018-06-21 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
IL260750B2 (en) 2016-03-04 2024-02-01 Morphosys Ag Clinical evaluation of protein-M response in multiple myeloma
JP7103950B2 (ja) * 2016-04-22 2022-07-20 アクセレロン ファーマ インコーポレーテッド Ａｌｋ７結合性タンパク質及びその使用
MX2018015592A (es) 2016-06-14 2019-04-24 Xencor Inc Anticuerpos inhibidores de puntos de control biespecificos.
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
US10478497B2 (en) 2016-07-20 2019-11-19 Hybrigenics S.A. Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
AU2017353427A1 (en) 2016-11-02 2019-05-16 Bristol-Myers Squibb Company Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
WO2018224682A1 (en) 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
US12161717B2 (en) 2017-06-08 2024-12-10 Black Belt Therapeutics Limited CD38 modulating antibody agents
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3668896A1 (en) 2017-08-16 2020-06-24 Black Belt Therapeutics Limited Cd38 modulating antibody
WO2019034753A1 (en) * 2017-08-16 2019-02-21 Tusk Therapeutics Ltd ANTIBODY CD38
EP3681908A1 (en) 2017-09-13 2020-07-22 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
BR112020005028A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento em combinação para câncer
JP7433222B2 (ja) 2017-10-25 2024-02-19 アクセレロン ファーマ インコーポレーテッド Ａｌｋ７結合タンパク質およびその使用
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
AU2018362014A1 (en) 2017-11-03 2020-05-28 Sorrento Therapeutics, Inc. CD38-directed chimeric antigen receptor constructs
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
KR102263812B1 (ko) * 2017-12-14 2021-06-14 에이비엘바이오 주식회사 a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도
CA3088199A1 (en) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
AU2019240111A1 (en) 2018-03-21 2020-09-17 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
KR20220080044A (ko) 2018-05-16 2022-06-14 얀센 바이오테크 인코포레이티드 암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
MX2020014265A (es) * 2018-06-20 2021-05-27 Sorrento Therapeutics Inc Anticuerpo variante que se une a cd38.
EP3820890A1 (en) 2018-07-13 2021-05-19 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
TW202019518A (zh) 2018-07-13 2020-06-01 丹麥商珍美寶股份有限公司 Ｃｄ３８抗體之變體及其用途
BR112021004130A2 (pt) 2018-09-11 2021-05-25 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd38, fragmento de ligação ao antígeno do mesmo, e uso farmacêutico
CN109293773B (zh) * 2018-09-25 2020-09-04 上海邦耀生物科技有限公司 靶向cd38蛋白的抗体、嵌合抗原受体和药物
EP3867275A2 (en) 2018-10-17 2021-08-25 Janssen Biotech, Inc. Method of providing subcutaneous administration of anti-cd38 antibodies
EP3870611A1 (en) 2018-10-26 2021-09-01 TeneoBio, Inc. Heavy chain antibodies binding to cd38
AU2019379858B2 (en) 2018-11-13 2024-01-04 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
WO2020120730A1 (en) * 2018-12-14 2020-06-18 Morphosys Ag Antibody formulations
BR112021014574A2 (pt) * 2019-01-23 2021-10-05 Encefa Competidores cd31 e usos dos mesmos
TW202102541A (zh) 2019-03-15 2021-01-16 德商莫菲西斯公司 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物
AU2020299600A1 (en) * 2019-07-03 2022-01-06 Crystal Bioscience Inc. Anti-CD38 antibody and methods of use thereof
AU2020351234A1 (en) * 2019-09-18 2022-04-28 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to CD38
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201916150D0 (en) 2019-11-06 2019-12-18 Univ Of Ireland Galway Treatment of multiple myeloma
WO2021112196A1 (ja) * 2019-12-05 2021-06-10 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
CA3158579A1 (en) 2019-12-18 2021-06-24 Pranjali DALVI Heavy chain antibodies binding to cd38
IL294453A (en) 2020-01-16 2022-09-01 Genmab As Formulations of cd38 antibodies and uses thereof
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
PE20230784A1 (es) 2020-05-19 2023-05-11 Boehringer Ingelheim Int Moleculas de fijacion para el tratamiento de cancer
CN111808193B (zh) * 2020-06-30 2022-04-05 源道隆（苏州）医学科技有限公司 可结合人cd38的纳米抗体及其应用
CN113861292A (zh) * 2020-06-30 2021-12-31 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
TW202233668A (zh) 2020-10-21 2022-09-01 德商百靈佳殷格翰國際股份有限公司 用於治療眼部疾病之雙特異性抗-VEGF及抗-TrkB結合分子
US20240109977A1 (en) 2021-01-14 2024-04-04 Morphosys Ag Anti-cd38 antibodies and their uses
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
AR126161A1 (es) 2021-06-17 2023-09-27 Boehringer Lngelheim Int Gmbh Moléculas de fijación triespecíficas novedosas
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
KR20240042442A (ko) 2021-07-28 2024-04-02 제넨테크, 인크. 혈액암 치료를 위한 IL15/IL15R 알파 이종이량체 Fc-융합 단백질
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
MX2024005406A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Reduccion de corticosteroides en el tratamiento con anticuerpos anti-cd38.
WO2023143547A1 (zh) * 2022-01-30 2023-08-03 百奥泰生物制药股份有限公司 抗cd28抗体及其应用
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
PE20250669A1 (es) 2022-07-15 2025-03-04 Boehringer Ingelheim Int Moleculas de union para el tratamiento del cancer
TW202432177A (zh) 2022-10-31 2024-08-16 丹麥商珍美寶股份有限公司 Ｃｄ３８抗體及其用途
IL320562A (en) 2022-11-02 2025-07-01 Janssen Biotech Inc Cancer treatment methods
AR131654A1 (es) 2023-01-20 2025-04-16 Boehringer Ingelheim Int PROTEÍNAS DE FUSIÓN Fc DE IL-12
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
CN119119277B (zh) * 2024-10-24 2025-09-09 深圳技术大学 一种靶向cd38的纳米抗体、药物组合物及其应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0250486A4 (en) * 1986-01-03 1988-05-25 Univ Melbourne MELPHALAN DERIVATIVES.
SU1595902A1 (ru) * 1988-06-30 1990-09-30 Всесоюзный онкологический научный центр АМН СССР Штамм гибридных культивируемых клеток животных MUS мUSсULUS L, используемый дл получени моноклональных антител к антигену СД38 кортикальных тимоцитов
US5156951A (en) * 1989-07-13 1992-10-20 Becton Dickinson And Company Detecting immunological changes in HIV infected patient samples
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
AU6123894A (en) 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
US6555324B1 (en) 1993-11-04 2003-04-29 Becton Dickinson & Company Method to distinguish hematopoietic progenitor cells
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
KR100449677B1 (ko) 1995-05-11 2004-11-20 어플라이드 리서치 시스템스 Il－6 활성 저해 물질
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US5594116A (en) 1995-11-08 1997-01-14 Promega Corporation Tryptase polyclonal antibody and purification method for use in human tryptase immunoassay
JP4233608B2 (ja) * 1996-10-15 2009-03-04 塩野義製薬株式会社 自己抗体測定方法
CA2329940A1 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) * 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
GB9903664D0 (en) 1999-02-17 1999-04-14 Isis Innovation Adjuvant and cell maturation agent
JP2000316578A (ja) 1999-05-12 2000-11-21 Bml Inc 糖尿病発症危険因子の検出方法
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US20020028488A1 (en) 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
EP1326998A4 (en) 2000-10-17 2005-05-11 Trudeau Inst Inc MODIFIED CHEMOTAXIS GENE CD38
US6892140B1 (en) 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
ES2389251T3 (es) 2000-12-19 2012-10-24 Altor Bioscience Corporation Animales transgénicos que comprenden un sistema inmunitario humanizado
US20040081981A1 (en) 2001-01-31 2004-04-29 Toru Egashira Method of detecting risk factor for onset of diabetes
CA2445168A1 (en) 2001-04-24 2002-10-31 Bayer Corporation Human timp-1 antibodies
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2463634A1 (en) 2001-10-15 2003-04-24 Kirin Beer Kabushiki Kaisha Anti-hla-dr antibody
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003091275A2 (en) 2002-04-23 2003-11-06 Andrea Savarino Compositions containing anti-hiv peptides and methods of use
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
CA2542840A1 (en) 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
PL2511297T3 (pl) 2004-02-06 2015-08-31 Morphosys Ag Ludzkie przeciwciała anty-CD38 i ich zastosowania
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
ATE446315T1 (de) 2004-02-13 2009-11-15 Boehringer Ingelheim Pharma Cd38-spleiss-varianten und deren anwendungen
WO2006099875A1 (en) 2005-03-23 2006-09-28 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
JP2008535494A (ja) 2005-04-07 2008-09-04 サグレシュ ディスカバリー， インコーポレイテッド 癌関連遺伝子（ｐｒｌｒ）
EP1888647A2 (en) * 2005-05-24 2008-02-20 MorphoSys AG Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
BRPI0618399B1 (pt) 2005-10-12 2023-10-03 Morphosys Ag Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN101883846A (zh) 2007-10-01 2010-11-10 科德克希思公司 用于生成氮杂环丁酮的还原酶多肽
BR112012008665A2 (pt) 2009-10-12 2016-11-22 Pfizer tratamento de câncer
SG188345A1 (en) * 2010-09-27 2013-04-30 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PL2900232T3 (pl) * 2012-09-25 2018-05-30 Morphosys Ag Kombinacje i ich zastosowania
WO2014068114A1 (en) * 2012-11-05 2014-05-08 Morphosys Ag Radiolabelled antibody and uses thereof
WO2020202527A1 (ja) 2019-04-04 2020-10-08 オリンパス株式会社 画像記録装置
US12491218B2 (en) 2019-06-30 2025-12-09 Uplift Food Inc Prebiotic and probiotic cookie preparation
US11920830B1 (en) 2022-11-11 2024-03-05 Russell Dwayne Mcnally Tool and method for cleaning and draining a water heater

Also Published As

Publication number Publication date
US20240309109A1 (en) 2024-09-19
CN101287764B (zh) 2013-11-13
CA2625681A1 (en) 2007-04-19
WO2007042309A3 (en) 2007-09-13
DK2860192T3 (en) 2018-01-02
KR20150139636A (ko) 2015-12-11
EP3284756B1 (en) 2021-05-05
CN103554259A (zh) 2014-02-05
TWI428444B (zh) 2014-03-01
US8486394B2 (en) 2013-07-16
ZA200803208B (en) 2009-02-25
CN106434683B (zh) 2020-03-13
ES2653664T3 (es) 2018-02-08
US20090252733A1 (en) 2009-10-08
IL190665B (en) 2018-06-28
KR101512853B1 (ko) 2015-04-28
RU2425841C2 (ru) 2011-08-10
CN103554259B (zh) 2016-05-18
LT2860192T (lt) 2017-12-11
US8088896B2 (en) 2012-01-03
US9193799B2 (en) 2015-11-24
CN106434683A (zh) 2017-02-22
US20190077877A1 (en) 2019-03-14
US20120052078A1 (en) 2012-03-01
KR101472250B1 (ko) 2014-12-11
NZ566915A (en) 2011-09-30
JP2009511033A (ja) 2009-03-19
SI2860192T1 (en) 2018-04-30
PL2860192T3 (pl) 2018-03-30
IL190665A0 (en) 2008-11-03
NO344961B1 (no) 2020-08-03
HK1122822A1 (zh) 2009-05-29
AU2006301446A1 (en) 2007-04-19
US10184005B2 (en) 2019-01-22
BRPI0618399B1 (pt) 2023-10-03
CA2625681C (en) 2016-08-02
CN103554260A (zh) 2014-02-05
EP2860192A3 (en) 2015-04-22
US20130273072A1 (en) 2013-10-17
EP2860192A2 (en) 2015-04-15
US20210292431A1 (en) 2021-09-23
PT2860192T (pt) 2017-12-26
US20160075796A1 (en) 2016-03-17
KR20140022427A (ko) 2014-02-24
US11939395B2 (en) 2024-03-26
TW200730624A (en) 2007-08-16
KR20080068056A (ko) 2008-07-22
AR105490A2 (es) 2017-10-11
JP5362359B2 (ja) 2013-12-11
EP2860192B1 (en) 2017-09-27
CY1119722T1 (el) 2018-06-27
JP5752667B2 (ja) 2015-07-22
NO20081972L (no) 2008-04-25
HUE035250T2 (hu) 2018-05-02
CN101287764A (zh) 2008-10-15
KR20140105029A (ko) 2014-08-29
EP3284756A1 (en) 2018-02-21
SG10201400973XA (en) 2014-08-28
US11059902B2 (en) 2021-07-13
KR101574920B1 (ko) 2015-12-04
RS56677B1 (sr) 2018-03-30
ME02886B (me) 2018-04-20
AU2006301446B2 (en) 2012-06-07
HK1194398A1 (zh) 2014-10-17
WO2007042309A2 (en) 2007-04-19
HRP20171978T1 (hr) 2018-04-06
RU2008111882A (ru) 2009-11-20
JP2013079238A (ja) 2013-05-02
EP1945671A2 (en) 2008-07-23
BRPI0618399A2 (pt) 2011-08-30

Similar Documents

Publication Publication Date Title
AR055191A1 (es) Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
MX2023004349A (es) Anticuerpos monoclonales anti-ccr8 y sus usos.
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
EA201790858A2 (ru) Лечение и профилактика амилоидоза
EA200700136A1 (ru) Анти-cd154-антитела
PE20091109A1 (es) Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c
DE602005011617D1 (de) Hochaffiner ny-eso-t-zellen-rezeptor
WO2006125640A3 (en) Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
MXPA01003344A (es) Composiciones y metodos para inmunoterapia especifica de wt1.
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
NO20083793L (no) Antistoffer mot amyloid-beta peptid
IN2014KN01715A (es)
RU2010119521A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
NZ591130A (en) Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
MX351682B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CO5601037A2 (es) Anticuerpos anti-a beta y sus usos
EP2400021A3 (en) ErbB3 based methods and compositions for treating neoplasms
GEP20135967B (en) Improved reconstituted surfactant composition containing surfactant protein b (sp-b), and surfactant protein c (sp-c) analogs
TN2009000099A1 (en) Reconstituted surfactants having improved properties
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
RU2012107993A (ru) Полипептиды porhyromonas gingivalis
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
BR9910568A (pt) Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos

Legal Events

Date Code Title Description
FG Grant, registration
FG Grant, registration